U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Bio-Rad Laboratories GmbH - 07/29/2016
  1. Warning Letters


Bio-Rad Laboratories GmbH

Bio-Rad Laboratories GmbH

United States

Issuing Office:

United States


Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
 Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

JUL 29 2016

Anita Glombik
General Manager
Bio-Rad Laboratories GmbH
Heidemannstrasse 164
Munchen, Germany 80939

Dear Ms. Glombik:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter [CMS#457793] dated September 3, 2015. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.



James L. Woods
Deputy Director
Patient Safety and Product Quality
Office of In Vitro Diagnostics and
     Radiological Health
Center for Devices and Radiological Health

Back to Top